Trial Profile
A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Aug 2017
Price :
$35
*
At a glance
- Drugs AT 501 (Primary)
- Indications Influenza A virus H7N9 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Medigen Vaccine Biologics; Medigen Vaccinology Corp
- 20 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 12 May 2015 New trial record